Abbott Laboratories gains attention as medical devices, diabetes care, cardiovascular products, and raised guidance ...

Rapid advancements in Chinese artificial intelligence models raise more questions about costly technology spending, as Google ...

Detailed price information for Abbott Laboratories (ABT-N) from The Globe and Mail including charting and trades.

Abbott Laboratories' strength in Medical Devices business and the recently acquired Exact Sciences should keep driving growth ...

Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street Abbott Laboratories (NYSE:ABT) reported second-quarter ...

Second-quarter reported sales growth of 13.0 percent; comparable sales growth of 4.8 percent Second-quarter GAAP diluted EPS of $0.53; adjusted diluted EPS of $1.31 ...

Abbott said on Thursday that its second quarter Diagnostics sales grew 42 percent to $3.09 billion compared to $2.17 billion in the year-ago quarter, helped along by its acquisition of Exact Sciences ...

The Exact Sciences acquisition, which closed in March, fueled more than 40% growth in Abbott’s diagnostics sales in the ...

Abbott (NYSE:ABT) shares are trading higher premarket on Thursday after the company reported second-quarter earnings, topping consensus expectations and raising its full-year earnings guidance.

Abbott Laboratories (NYSE:ABT) released second-quarter financial results and hosted an earnings call on Thursday. Read the ...

Jorge Garces, who joined Abbott to oversee scientific strategy for cancer diagnostics after it acquired Exact Sciences, ...

ABT heads into Q2 earnings results with growth expected across Diagnostics, Devices and EPD, while Nutrition remains a drag.